Regen BioPharma, Inc. (RGBP)
USD 0.07
(-16.47%)
USD 0.07
(-16.47%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 756.2 Thousand USD | -40.65% |
| 2022 | 1.27 Million USD | -64.44% |
| 2021 | 3.58 Million USD | 37.55% |
| 2020 | 2.6 Million USD | 21.32% |
| 2019 | 2.14 Million USD | 49.92% |
| 2018 | 1.43 Million USD | 106.78% |
| 2017 | 692.65 Thousand USD | 166.87% |
| 2016 | 259.54 Thousand USD | 16.52% |
| 2015 | 222.75 Thousand USD | 76.36% |
| 2014 | 126.3 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 714.07 Thousand USD | -5.57% |
| 2024 Q2 | 693.77 Thousand USD | -2.84% |
| 2024 Q3 | 739.11 Thousand USD | 3.65% |
| 2023 Q2 | 611.59 Thousand USD | 19.55% |
| 2023 Q1 | 511.59 Thousand USD | -59.85% |
| 2023 FY | 756.2 Thousand USD | -40.65% |
| 2023 Q4 | 756.2 Thousand USD | 23.65% |
| 2023 Q3 | 611.59 Thousand USD | 0.0% |
| 2022 Q1 | 2.72 Million USD | -23.95% |
| 2022 Q2 | 2.99 Million USD | 10.04% |
| 2022 Q4 | 1.27 Million USD | -19.48% |
| 2022 FY | 1.27 Million USD | -64.44% |
| 2022 Q3 | 1.58 Million USD | -47.23% |
| 2021 Q3 | 2.37 Million USD | -6.57% |
| 2021 Q2 | 2.54 Million USD | -1.55% |
| 2021 Q1 | 2.58 Million USD | -0.7% |
| 2021 Q4 | 3.58 Million USD | 50.59% |
| 2021 FY | 3.58 Million USD | 37.55% |
| 2020 FY | 2.6 Million USD | 21.32% |
| 2020 Q1 | 2.2 Million USD | 2.9% |
| 2020 Q2 | 2.39 Million USD | 8.56% |
| 2020 Q3 | 2.53 Million USD | 5.63% |
| 2020 Q4 | 2.6 Million USD | 2.81% |
| 2019 FY | 2.14 Million USD | 49.92% |
| 2019 Q3 | 1.92 Million USD | 4.19% |
| 2019 Q2 | 1.84 Million USD | 12.61% |
| 2019 Q4 | 2.14 Million USD | 11.66% |
| 2019 Q1 | 1.63 Million USD | 14.43% |
| 2018 FY | 1.43 Million USD | 106.78% |
| 2018 Q4 | 1.43 Million USD | 16.78% |
| 2018 Q3 | 1.22 Million USD | 15.46% |
| 2018 Q1 | 936.3 Thousand USD | 35.18% |
| 2018 Q2 | 1.06 Million USD | 13.45% |
| 2017 FY | 692.65 Thousand USD | 166.87% |
| 2017 Q4 | 692.65 Thousand USD | 39.23% |
| 2017 Q3 | 497.5 Thousand USD | 45.11% |
| 2017 Q1 | 245.83 Thousand USD | -5.28% |
| 2017 Q2 | 342.84 Thousand USD | 39.46% |
| 2016 Q2 | 286.34 Thousand USD | 70.39% |
| 2016 FY | 259.54 Thousand USD | 16.52% |
| 2016 Q1 | 168.05 Thousand USD | -24.56% |
| 2016 Q4 | 259.54 Thousand USD | -30.26% |
| 2016 Q3 | 372.15 Thousand USD | 29.97% |
| 2015 Q4 | 222.75 Thousand USD | 114.7% |
| 2015 Q2 | 133.75 Thousand USD | -56.28% |
| 2015 Q1 | 305.89 Thousand USD | 142.18% |
| 2015 Q3 | 103.75 Thousand USD | -22.43% |
| 2015 FY | 222.75 Thousand USD | 76.36% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | 50 Thousand USD | 0.0% |
| 2014 FY | 126.3 Thousand USD | 0.0% |
| 2014 Q4 | 126.3 Thousand USD | 152.61% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 98.165% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 81.654% |
| SQZ Biotechnologies Company | 27.47 Million USD | 97.247% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 98.257% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 97.46% |
| Mesoblast Limited | 118.7 Million USD | 99.363% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 20.254% |
| Genus plc | 233.1 Million USD | 99.676% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 74.194% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 43.717% |
| Marizyme, Inc. | 18.71 Million USD | 95.96% |
| ContraFect Corporation | 2.88 Million USD | 73.752% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -0.827% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -458.138% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 47.715% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 67.488% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 86.636% |
| MultiCell Technologies, Inc. | 202.58 USD | -373186.603% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 98.685% |
| EV Biologics, Inc. | 1.49 Million USD | 49.409% |
| Q BioMed Inc. | 4.1 Million USD | 81.601% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 97.715% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -20.018% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 38.438% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2.809% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.559% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 94.182% |
| Skye Bioscience, Inc. | 4.61 Million USD | 83.615% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 14.848% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -434.352% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 87.12% |
| IMV Inc. | 28.88 Million USD | 97.382% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -2840.254% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 66.516% |
| GB Sciences, Inc. | 1.75 Million USD | 57.017% |
| Alpha Cognition Inc. | 1.22 Million USD | 38.035% |
| HST Global, Inc. | 98.31 Thousand USD | -669.133% |
| CSL Limited | 12.18 Billion USD | 99.994% |
| Halberd Corporation | 150 Thousand USD | -404.136% |
| Enzolytics Inc. | 996.33 Thousand USD | 24.102% |
| Resverlogix Corp. | 6.49 Million USD | 88.35% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -58.367% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -195.864% |
| argenx SE | 20 Million USD | 96.219% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 98.34% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 72.082% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -7295.638% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.819% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -276.941% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 68.462% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -229.801% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.882% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 75.011% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -110.226% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 96.28% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -408.701% |
| BioStem Technologies, Inc. | 4.71 Million USD | 83.95% |
| ONE Bio Corp. | 19.71 Million USD | 96.164% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -202.262% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -204.038% |
| Agentix Corp. | 50 Thousand USD | -1412.408% |
| LadRx Corporation | 33.6 Thousand USD | -2150.205% |
| Cell Source, Inc. | 9.25 Million USD | 91.829% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 0.0% |
| NovAccess Global Inc. | 2.19 Million USD | 65.625% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 89.308% |
| Itoco Inc. | 228.37 Thousand USD | -231.121% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -258.433% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 84.824% |
| Kadimastem Ltd | 891.22 Thousand USD | 15.15% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -88.181% |
| CytoDyn Inc. | 30.07 Million USD | 97.486% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -56.149% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -114.924% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 90.33% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -517.309% |
| Rebus Holdings, Inc. | 310 Thousand USD | -143.937% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 84.03% |
| International Stem Cell Corporation | 4.17 Million USD | 81.9% |
| Bioxytran, Inc. | 1.92 Million USD | 60.717% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1111.613% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 65.326% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 90.907% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 91.192% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 51.384% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -182.166% |
| Neutra Corp. | 54.15 Thousand USD | -1296.344% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 58.677% |
| PureTech Health plc | 25.51 Million USD | 97.036% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 38.23% |
| IXICO plc | 472.02 Thousand USD | -60.205% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 95.122% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.785% |
| CSL Limited | 12.18 Billion USD | 99.994% |
| Cellectis S.A. | 92.77 Million USD | 99.185% |